

## Limited Submission Funding Opportunities – updated 8/21/20

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of \$50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at [ecor@mgh.harvard.edu](mailto:ecor@mgh.harvard.edu)

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

### Process

Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to [ecor@mgh.harvard.edu](mailto:ecor@mgh.harvard.edu). In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at [ecor@mgh.harvard.edu](mailto:ecor@mgh.harvard.edu).

### CURRENT OPPORTUNITIES

#### 1. Claude D. Pepper Older Americans Independence Centers (P30 Clinical Trial Optional)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-024.html>

**MGH LOI Deadline: 9/08/20**

NIH LOI Deadline: 9/29/20

NIH Application Deadline: 10/29/20

This FOA supports applications for Claude D. Pepper Older Americans Independence Centers (OAICs), centers of excellence in geriatrics research and research education, to increase scientific knowledge leading to better ways to maintain or restore independence in older persons. The OAIC awards are

## Limited Submission Funding Opportunities – updated 8/21/20

designed to develop or strengthen awardee institutions' programs that focus on and sustain progress in a key area in aging research related to the mission of the OAIC program.

### 2. Livestrong Solution Grants – Acceleration and Transformation Grants

<https://www.livestrong.org/what-we-do/livestrong-solution-grants>

**MGH LOI Deadline: 9/14/20**

Sponsor LOI Deadline: 10/16/20

Sponsor Application Deadline: 12/07/20

The Livestrong Solution Grants program recognizes and funds organizations who are developing cutting edge, inventive, and sustainable solutions to overlooked cancer problems. Projects and organizations funded must directly align with Livestrong's mission and purpose. Livestrong focus areas and funding priorities include:

- Post-treatment care
- Patient and caregiver education
- Comprehensive quality of life services
- Streamlining systems and care

In addition, the projects must have measurable outcomes, and be sustainable for the duration of the grant. Finally, projects must not replicate existing [Livestrong programs](#).

Organizations are eligible to submit **one application for each funding tier (i.e. Acceleration Grant and/or Transformation Grant) per funding cycle.**

### 3. Collaborative Centers in Children's Environmental Health Research and Translation (P2C Clinical Trial Optional)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-20-001.html>

**MGH LOI Deadline: 9/22/20**

NIH LOI Deadline: 10/23/20

NIH Application Deadline: 11/23/20

To accelerate the movement of research findings to action, NIEHS invites grant applications from institutions/organizations that propose to build a Collaborative Center in Children's Environmental Health Research and Translation (CEHRT Center). Centers are charged with developing effective strategies to translate key children's environmental health (CEH) research findings to relevant stakeholders in the community, academia and practice.

The overall goal of this FOA is the creation of a national network of children's environmental health translation centers. Through external collaboration with the children's environmental health community, Centers will protect and improve children's health by developing and testing new scientific questions and public health interventions/strategies with an eye towards translation; and mentoring a pipeline of new investigators interested in translational CEH.

CEHRT centers will serve as leaders in CEH translational research and research methodology development, with a focus on creating actionable steps to move evidence-informed biomedical, behavioral, psychosocial, environmental research findings in children's environmental health to the

## Limited Submission Funding Opportunities – updated 8/21/20

wider community. The collective collaborative center program will also serve as a national research resource to support response efforts to emerging environmental exposures affecting children.

### 4. Liver Cirrhosis Network: Clinical Research Centers (U01 Clinical Trial Required) – NEW!

<https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-003.html>

**MGH LOI Deadline: 10/01/20**

NIH LOI Deadline: 11/01/20

NIH Application Deadline: 12/01/20

The NIDDK is proposing the establishment of the Liver Cirrhosis Network through this Funding Opportunity Announcement which is seeking Clinical Centers; and in conjunction with RFA-DK-20-004 seeking a single Scientific Data Coordination Center, in order to promote clinical and translational research on cirrhosis of the liver in adults.

### 5. Liver Cirrhosis Network: Scientific and Data Coordination Center (U24 Clinical Trial Optional) – NEW!

<https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-004.html>

**MGH LOI Deadline: 10/01/20**

NIH LOI Deadline: 11/01/20

NIH Application Deadline: 12/01/20

The NIDDK is proposing the establishment of the Liver Cirrhosis Network through this Funding Opportunity Announcement which is seeking a single Scientific Data Coordination Center; and in conjunction with RFA-DK-20-003 seeking Clinical Research Centers, in order to promote clinical and translational research on cirrhosis of the liver in adults.

### 6. Martin Delaney Collaboratories for HIV Cure Research (UM1 Clinical Trial Not Allowed) and Martin Delaney Collaboratory for Pediatric HIV Cure Research (UM1 Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-035.html>

**MGH LOI Deadline: 10/07/20**

NIH LOI Deadline: 11/07/20

NIH Application Deadline: 12/07/20

**Only one application per institution is allowed between the two RFAs. An institution may not submit to the adult HIV Cure Research RFA and the Pediatric HIV Cure Research RFA at the same time.**

The purpose of this Funding Opportunity Announcement (FOA) is to address the problem of HIV persistence in people living with HIV treated with suppressive antiretroviral drug regimens. This FOA will support coordinated basic, clinical, and applied research focused on developing strategies to achieve an HIV cure, defined as either sustained viral remission or eradication of HIV infection. While some aspect of clinical research is required, unlike the previous iteration of this RFA, clinical trials will no longer be supported. The application must include at least one private sector entity to facilitate rapid translation of basic discovery research into therapeutic development and testing. Collaboratory research should be milestone-based and should be focused on specific innovative approaches to characterize and quantify persistent HIV-1 reservoirs and/or understand and predict post-treatment control of viral rebound, identify and test therapeutic strategies to control viral rebound after discontinuation of antiretroviral

## Limited Submission Funding Opportunities – updated 8/21/20

therapy, and identify and test strategies to eradicate or permanently inactivate rebound-competent HIV.

### 7. NIH Neuroscience Development for Advancing the Careers of a Diverse Research Workforce (R25 Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/pa-files/PAR-20-240.html>

**MGH LOI Deadline: 11/16/20**

NIH LOI Deadline: 12/26/20

NIH Application Deadline: 1/25/21

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on:

- ***Research Experiences***
- ***Mentoring Activities***
- ***Curriculum or Methods Development***